Press Center

APR Applied Pharma Research s.a. and Labtec GmbH announce the European Approval of Ondansetron Rapidfilm®, co-developed in partnership with MonoSol Rx and licensed to BioAlliance Pharma SA for EU countries. >>

Active ingredients pass through the skin or dissolve on the tongue >>

Interview with Joachim Suesse, Head of the Business Unit tesa Health Markets >>

SciClone Pharmaceuticals, Inc. and APR Applied Pharma Research S.A. have entered into an exclusive licensing agreement granting SciClone the commercialization rights for APR’s innovative anti-nausea drug Ondansetron Rapidfilm® for China and Vietnam. >>

Abdi Ibrahim Pharmaceuticals and APR Applied Pharma Research SA, together with its joint venture partner Labtec GmbH, have entered into an exclusive licensing agreement under which Abdi Ibrahim has the exclusive rights to market Ondansetron Rapidfilm® in Turkey. >>

Acquisition of Labtec opens up new line of business for tesa >>

The French company BioAlliance Pharma has submitted an EU marketing application for its RapidFilm oral film-strip formulation of ondansetron. >>

Investment in new segment of the health care sector >>

BioAlliance Pharma S.A., the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, and Applied Pharma Research S.A., together with Labtec GmbH, have entered into an exclusive licensing agreement. >>

APR Applied Pharma Research s.a. and Labtec GmbH announce the successful completion of the pilot bioequivalence study of their Donepezil Rapidfilm® further confirming the validity and adaptability of this innovative proprietary technology. >>

On the basis of bioequivalence assessed in this pivotal study, therapeutic equivalence between Ondansetron Rapidfilm® and Zofran ODT® could successfully be demonstrated. >>